2020 American Transplant Congress
Re-Examining Sex-Based Differences in Liver Transplant Outcomes for HCV Cirrhosis
*Purpose: Previous studies have demonstrated that female liver transplant recipients with hepatitis C (HCV) are at increased risk for graft failure due to disease recurrence…2020 American Transplant Congress
Kidney Transplantation from Hepatitis C Infected Donors to Hepatitis C Negative Recipients: Does Organs Selection Matter?
*Purpose: Recently, there has been a marked increase in the availability and use of kidneys from hepatitis C virus (HCV) positive deceased donors for transplantation.…2020 American Transplant Congress
Incidence of Cytomegalovirus Infection in Deceased Donor Kidney Transplantation from Hepatitis-C Antibody Positive Donors to Hepatitis-C Antibody Negative Recipients: A National Registry Analysis
*Purpose: Deceased donor kidney transplantation (KT) from hepatitis C (HCV) infected donors into HCV uninfected recipients (HCV D+/R-) will be the standard of care in…2020 American Transplant Congress
Using HCV Infected Organs and the Challenge of Third-Party Payers
Comprhensive Transplant Center, The Ohio State University, Columbus, OH
*Purpose: The practice of transplanting organs from hepatitis C viremic donors (HCV NAT+) into negative recipients hinges on the ability to ensure direct acting antiviral…2020 American Transplant Congress
Exploring the Uneven Geographic Distribution of Hepatitis C-Viremic Deceased Donors in the US
University of Miami, Miami, FL
*Purpose: There has been a marked increase in the utilization of organs from hepatitis C virus (HCV) viremic donors due to the rise of drug-related…2020 American Transplant Congress
A Successful Kidney Transplantation from Hepatitis C NAT Positive Deceased Donor to an HIV Positive Recipient with Previous History of Treated HCV Infection
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Due to a shortage of deceased donor kidney organs, increased waiting times have been associated with adverse outcomes post kidney transplantation. The recent breakthrough…2020 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
*Purpose: Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of HCV has shifted in the last few…2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…2020 American Transplant Congress
Unrealized Potential Utilization of HCV+ Deceased-Donor Kidneys and Livers
*Purpose: In the era of new, direct-acting antiviral therapy for hepatitis C virus (HCV), HCV+ deceased-donor organs can be transplanted into HCV- recipients with excellent…2020 American Transplant Congress
Transplantation of HCV Positive Kidneys Confers Excellent Outcomes for HCV Infected and Uninfected Recipients
Montefiore Medical Center, Bronx, NY
*Purpose: Hepatitis C positive (HCV+) donor kidneys were previously transplanted only into HCV infected recipients (D+/R+). Availability of direct acting anti-virals (DAA) has facilitated the…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 28
- Next Page »